A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunogenicity of a booster vaccination with an adapted recombinant protein RBD fusion homodimer candidate (PHH-1V81) against SARS-CoV-2, in adults vaccinated against COVID-19.
CompletedCTIS2023-508458-25-00
Hipra Scientific S.L., Hipra Scientific S.L.COVID-19 disease
Start: 2023-11-13End: 2024-06-17Target: 612Updated: 2024-02-08